Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study

被引：5
|
作者：
Porta, C. G. [1 ]
Eto, M. [2 ]
Motzer, R. J. [3 ]
De Giorgi, U. F. F. [4 ]
Buchler, T. [5 ]
Basappa, N. S. [6 ]
Mendez Vidal, M. J. [7 ]
Tjulandin, S. [8 ]
Park, S. H. [9 ]
Melichar, B. [10 ]
Hutson, T. E. [11 ]
Alemany, C. [12 ]
McGregor, B. [13 ]
He, C. S. [14 ]
Perini, R. [15 ]
Mody, K. [16 ]
McKenzie, J. [16 ]
Choueiri, T. K. [13 ]
机构：
[1] Univ Bari A Moro, Interdisciplinary Dept Med, Bari, Italy
[2] Kyushu Univ, Dept Urol, Fukuoka, Japan
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[4] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Dept Med Oncol, Meldola, Italy
[5] Thomayer Univ Hosp, Dept Oncol, Prague, Czech Republic
[6] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada
[7] Hosp Univ Reina Sofia, Maimonides Inst Biomed Res Cordoba, Dept Med Oncol, Cordoba, Spain
[8] Minist Hlth Russian Federat, NN Blokhin Natl Med Res Ctr Oncol, Dept Clin Pharmacol & Chemotherapy, Moscow, Russia
[9] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[10] Palacky Univ, Med Sch & Teaching Hosp, Dept Oncol, Olomouc, Czech Republic
[11] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dept Med Oncol, Dallas, TX USA
[12] AdventHlth Canc Inst, Dept Hematol & Oncol, Orlando, FL USA
[13] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[14] Eisai Inc, Biostat, Nutley, NJ USA
[15] Merck & Co Inc, Clin Res, Rahway, NJ USA
[16] Eisai Inc, Clin Res, Nutley, NJ USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1449MO
引用
收藏
页码：S1205 / +
页数：2
相关论文
共 50 条
  • [1] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, Camillo G.
    Eto, Masatoshi
    Motzer, Robert J.
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    He, Cixin Steven
    Perini, Rodolfo
    Mody, Kalgi
    McKenzie, Jodi
    Ebaid, Basant
    Choueiri, Toni
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 122 - 123
  • [2] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
    Voss, Martin H.
    Powles, Thomas
    McGregor, Bradley Alexander
    Porta, Camillo
    Gruenwald, Viktor
    Merchan, Jaime R.
    Rolland, Frederic
    Maroto-Rey, Pablo
    Goh, Jeffrey C.
    Xing, Dongyuan
    Perini, Rodolfo F.
    McKenzie, Jodi
    Mody, Kalgi
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
    Rha, Sun Young
    Choueiri, Toni K.
    Matveev, Vsevolod B.
    Alyasova, Anna
    Hong, Sung-Hoo
    Gordoa, Teresa Alonso
    Gurney, Howard
    Bjarnason, Georg A.
    Buchler, Tomas
    Pedrazzoli, Paolo
    Takagi, Toshio
    Park, Se Hoon
    Lee, Jae-Lyun
    Perini, Rodolfo F.
    He, Cixin
    McKenzie, Jodi A.
    Eto, Masatoshi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) plus pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
    Grunwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Gordoa, Teresa Alonso
    Eto, Masatoshi
    Hutson, Thomas E.
    Motzer, Robert J.
    Winquist, Eric
    Maroto-Rey, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    Smith, Alan D.
    Porta, Camillo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Mendez Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Merchan, Jaime R.
    Smith, Alan D.
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing Dongyuan
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Porta, Camillo
    Alekseev, Boris
    Rha, Sun Young
    Choueiri, Toni K.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Goh, Jeffrey C.
    Eto, Masatoshi
    Wang, Jinyi
    Pan, Janice
    Asfaw, Alemseged Ayele
    He, Cixin Steven
    Mody, Kalgi
    Cella, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
    Haro-Silerio, Jaime Ivan
    Johns, Andrew
    Moussa, Mohammad Jad
    Wang, Mindy
    Wang, Emily
    Kovitz, Craig A.
    Campbell, Matthew T.
    Jonasch, Eric
    Shah, Amishi Yogesh
    Tannir, Nizar M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433
  • [8] Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma
    Lee, Chung-Han
    DiNatale, Renzo G.
    Chowell, Diego
    Krishna, Chriag
    Makarov, Vladimir
    Shapnik, Natalie
    Murray, Samuel J.
    Carlo, Maria Isabel
    Voss, Martin H.
    Feldman, Darren R.
    Hakimi, A. Ari
    Adachi, Yusuke
    Minoshima, Yukinori
    Matsui, Junji
    Funahashi, Yasuhiro
    Perini, Rodolfo F.
    Nomoto, Kenichi
    Motzer, Robert J.
    Chan, Timothy An-thy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
    Grunwald, Viktor
    Motzer, Robert J.
    Keizman, Daniel
    Bedke, Jens
    Schmidinger, Manuela
    Staehler, Michael D.
    Matveev, Vsevolod B.
    George, Saby
    Hutson, Thomas E.
    Vaishampayan, Ulka N.
    Merchan, Jaime R.
    Eto, Masatoshi
    Rha, Sun Young
    Waddell, Tom
    Sabbatini, Roberto
    Barthelemy, Philippe
    Burgents, Joseph E.
    Ren, Min
    Brown, Ian
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    [J]. CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
12345